Myriad Genetics, Inc. (MYGN) 2013年年度报告「NASDAQ」.pdf

1、2013ANNUAL REPORTMYRIAD GENETICS,INC.320 Wakara WaySalt Lake City,Utah 2013ANNUAL REPORTMYRIAD GENETICS,INC.320 Wakara WaySalt Lake City,Utah Fiscal Year 2014 Product LaunchesmyRisk Hereditary Cancer is our next generation hereditary cancer panel.myRisk Hereditary Cancer will provide the most compre

2、hensive assessment of inherited cancer in any product available by analyzing 25 genes associated with breast,ovarian,colon,endometrial,pancreatic,lung,prostate cancer,and melanoma.Launched in September 2013,this test will dramatically improve patient care by detecting more patients at high risk for

3、hereditary cancer and allowing them to take appropriate steps to reduce their overall cancer risk.myPath Melanoma is a groundbreaking new test filling a significant unmet medical need in dermatology.With a planned launch in 2014,this test will aid dermatopathologists in correctly classifying the mor

4、e than 275,000 skin biopsy lesions which are classified as indeterminate each year.Today these indeterminate results lead to missed cancers or unnecessary treatment,adding a substantial cost burden to the healthcare system.myPlan Lung Cancer is our exciting lung cancer prognostic test.With a planned

5、 launch in 2014,this test will provide a detailed assessment of a patients risk for lung cancer related death and recurrence in early stage lung cancer patients.This information can be utilized by the physician and patient to more appropriately select whether or not to undergo chemotherapy following

6、 the initial surgery.Myriad is a pioneer in the field of molecular diagnostics as we seek to improve the quality of patients lives through innovative products.Patients and physicians look to our company as a trusted advisor to guide critical healthcare decisions and improve the healthcare management